Loading…
Reported covered position: Advisor to the Assistant Secretary for Preparedness & Response, HHS; Advisor to the Assistant Secretary of Legislation, HHS; Health Care Policy Fellow, Representative Michael Burgess
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm: TODD STRATEGY GROUP
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: PFIZER INC. · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
FERRING PHARMACEUTICALS INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · 4T
Issues pertaining to reproductive health and access and coverage of infertility treatments and care. Issues related to infectious disease and hospital acquired infections.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PFIZER INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Source: Senate LDA
| NOVARTIS, INC. |
| 15 |
| 2021–2025 |
| ADULT VACCINE ACCESS COALITION | 14 | 2022–2024 |
| PUERTO RICO DEPARTMENT OF HEALTH | 14 | 2021–2024 |
| FERRING PHARMACEUTICALS, INC. | 12 | 2023–2025 |
| GINKGO BIOSECURITY | 12 | 2023–2025 |
| VAXESS TECHNOLOGIES, INC | 12 | 2021–2024 |
| THE ORTHOFORUM | 11 | 2023–2025 |
| Alnylam Pharmaceuticals, Inc. | 10 | 2023–2025 |
| GILEAD SCIENCES, INC. | 10 | 2023–2025 |
| GRAND RIVER ASEPTIC MANUFACTURING | 10 | 2021–2023 |
| MEDICAL COUNTERMEASURES COALITION | 10 | 2024–2025 |
| PUERTO RICO FINANCIAL AND FISCAL AUTHORITY | 10 | 2021–2023 |
| ALKERMES, INC. | 9 | 2023–2025 |
| AMERICAN MEDICAL ASSOCIATION | 9 | 2023–2025 |
| ILLUMINA, INC. | 9 | 2023–2025 |
| KARIUS, INC. | 9 | 2022–2024 |
| MYRIAD GENETICS INC | 9 | 2023–2025 |
| TEXAS A&M HEALTH SCIENCE CENTER | 9 | 2021–2023 |
| EXELIXIS, INC. | 8 | 2023–2024 |
| HEALTH SUPPLY US LLC | 8 | 2023–2024 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | 2023–2024 |
| EMD SERONO, INC. | 7 | 2023–2025 |
| JOHNSON & JOHNSON SERVICES, INC. | 7 | 2023–2024 |
| KALDEROS, INC. | 7 | 2024–2025 |
| NOVO NORDISK, INC. | 7 | 2023–2024 |
| PMI US CORPORATE SERVICES INC. | 7 | 2023–2024 |
| U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER | 7 | 2024–2025 |
| ALEXION PHARMACEUTICALS, INC. | 6 | 2023–2024 |
| AVS BIO | 6 | 2024 |
| BIOGEN, INC. | 6 | 2023–2024 |
| HOSPICE COMPASSUS | 6 | 2021–2024 |
| NETLIST, INC. | 6 | 2023–2024 |
| NOMI HEALTH, INC. | 6 | 2024 |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | 6 | 2023–2024 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 6 | 2023–2024 |
| SIDECAR HEALTH | 6 | 2023–2024 |
| SOUTHWEST TRANSPLANT ALLIANCE | 6 | 2023–2024 |
| THE COALITION FOR 21ST CENTURY MEDICINE | 6 | 2023–2024 |
| AMERICAN COLLEGE OF RADIOLOGY | 5 | 2023–2024 |
| BRISTOL-MYERS SQUIBB COMPANY | 5 | 2023–2024 |
| FLOW THERAPY | 5 | 2022 |
| GENMAB | 5 | 2023–2024 |
| MED CLAIMS COMPLIANCE CORPORATION | 5 | 2024–2025 |
| PFIZER, INC. | 5 | 2023–2025 |
| SYNTHETIC BIOLOGY COALITION | 5 | 2021–2022 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 5 | 2023–2024 |
| AMERICAN POLICY VENTURES ACTION | 4 | 2024 |
| AMERICAN SOCIETY OF NEPHROLOGY | 4 | 2024 |
| ASTELLAS PHARMA US, INC. | 4 | 2024 |
| ASTRAZENECA PHARMACEUTICALS LP | 4 | 2022–2023 |
| Cepheid | 4 | 2023–2024 |
| DH DIAGNOSTICS, LLC | 4 | 2024 |
| ELI LILLY AND COMPANY | 4 | 2024 |
| EMD MILLIPORE | 4 | 2023 |
| FLEXCARE | 4 | 2024–2025 |
| MUTUAL OF OMAHA | 4 | 2024 |
| OSRX PHARMACEUTICALS | 4 | 2024 |
| VALISURE | 4 | 2025 |
| VAXART INC. | 4 | 2025 |
| WINE & SPIRITS WHOLESALERS OF AMERICA | 4 | 2025 |
| CORMEDIX, INC. | 3 | 2023–2024 |
| KALEO | 3 | 2025 |
| MILLIPORESIGMA | 3 | 2025 |
| EMERGENT BIOSOLUTIONS INC. | 2 | 2023 |
| GRAIL, Inc. | 2 | 2023–2024 |
| HORIZON THERAPEUTICS USA, INC. | 2 | 2023 |
| UCB, INC. | 2 | 2023 |
| VARIAN MEDICAL SYSTEMS, INC. | 2 | 2021 |
| ALLIANCE FOR CELL THERAPY NOW | 1 | 2022 |
| FOX CORPORATION | 1 | 2025 |
| ORGANIZE.ORG | 1 | 2021 |
| TRUIST FINANCIAL CORPORATION | 1 | 2025 |
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS, INC. · Firm: TODD STRATEGY GROUP
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Home infusion.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Home infusion.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Drug Pricing. S.864 - HELP Copays Act.
Drug Pricing. S.864 - HELP Copays Act.
Drug Pricing. S.864 - HELP Copays Act.
Drug Pricing. S.864 - HELP Copays Act.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Drug pricing policy. Implementation of Inflation Reduction Act of 2022. S.864 - HELP Copays Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, INC. · Firm: TODD STRATEGY GROUP
Issues related to oncology and multi cancer early detection, including diagnostics and screening. H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Labor, HHS and Education appropriations bill. H.R.3561 Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R. 4507 ACA Exchanges.
Appropriations. Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R.4507 - Transparency in Coverage Act of 2023.
Labor, HHS and Education appropriations bill. H.R.3561 Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R. 4507 ACA Exchanges.
Appropriations. Monitored issues related to consumer directed health care and transparency. Issues related to surprise medical billing. Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R.4507 - Transparency in Coverage Act of 2023.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Consumer-directed health care and transparency. H.R.5378 - Lower Costs, More Transparency Act.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Medicare and Medicaid Issues. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home infusion.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Maintaining Investments in New Innovation Act
Client: ALEXION PHARMACEUTICALS, INC. · Firm: TODD STRATEGY GROUP
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: TODD STRATEGY GROUP
Value of Prescription Drugs. Drug pricing. Biopharmaceutical Innovation and Patient Policy Issues. PSA Screening for HIM Act. H.R.8223/S.4246 - Advancing Menopause Care and Mid-Life Womens Health Act. Pharmacy Benefit Manager reform. Issues related to March-In
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: TODD STRATEGY GROUP
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues. PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act. Pharmacy Benefit Manager reform. Issues related to March-In.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: ASTELLAS PHARMA US, INC. · Firm: TODD STRATEGY GROUP
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues. PSA Screening for HIM Act; H.R. 8223/S. 4246 Advancing Menopause and Mid-Life Womens Health Act. Pharmacy Benefit Manager reform. Issues related to March-In.
Drug Pricing. H.R. 830 HELP Copays Act.
Drug Pricing. H.R. 830 HELP Copays Act.
Medicare Reimbursement for New Technologies. 340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.
Drug Pricing. H.R. 830 HELP Copays Act.
340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.
Drug Pricing. H.R. 830 HELP Copays Act.
Drug Pricing. H.R. 830 HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort litigation reform. Health Care Supply Chain. S.1375/H.R.830 - HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.
340B Program. Home Infusion for Part B Products. H.R.830 - HELP Copays Act. Medicare Reimbursement for New Technologies.
340B. Home Infusion for Part B Products. H.R.830 - HELP Copays Act.
Pharmacy Benefit Managers. Tort litigation reform. Health Care Supply Chain. S.1375/H.R.830 - HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. 340B. Tort litigation reform. Health Care Supply Chain. S.1375/H.R.830 - HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
Pharmacy Benefit Managers. Tort litigation reform. Health Care Supply Chain. S.1375/H.R.830 - HELP Copays Act.
Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation.
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
Patent Issues. Support for PREVAIL Act (S.2220). Support for Patent Eligibility Restoration Act (PERA) (S. 2140).
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Medicare and Medicaid Issues. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Medicare and Medicaid Issues H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act. Home Infusion.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.5547/S.476 - Maintaining Investments in New Innovation (MINI) Act. H.R.5539/S.3131 - ORPHAN Cures Act.
Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act.
Issues related to tariff and trade policy. International Supply Chain.
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PFIZER INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to tariff and trade policy. International Supply Chain.
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
PFIZER INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Issues related to FDA regulation of pharmaceuticals. H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. S.832 - EPIC Act of 2025.
Issues related to tariff and trade policy. International Supply Chain.
Issues related to tariff and trade policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
WINE & SPIRITS WHOLESALERS OF AMERICA via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Tax policy related to qualified business investment tax credit.
Filing targets: SENATE
VAXART INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Vaccine policy.
Filing targets: Health & Human Services, Dept of (HHS)
VALISURE via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Drug product quality assurance.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE ORTHOFORUM via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Physician Reimbursement. Physician-owned hospitals. Medicare and Medicaid Issues. Payment Reform. Price transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Prior Authorization for Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
MILLIPORESIGMA via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK & CO., INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues.
Drug Pricing. S.864 - HELP Copays Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL COUNTERMEASURES COALITION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Sustainability of the public health emergency medical countermeasure enterprise.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Prescription drug pricing. Medical countermeasure development and procurement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS)
KALDEROS, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Government pricing discounts. Claims adjudication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERIMETER SYSTEMS, INC. FKA GINKGO BIOSECURITY via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Biosecurity Issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Prescription drug payment reform. Supply chain. Strategic National Stockpile.
Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FERRING PHARMACEUTICALS INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Issues pertaining to reproductive health and access and coverage of infertility treatments and care. Issues related to infectious disease and hospital acquired infections.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIODESIX, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Medicare reimbursement for diagnostics. Medicare Contractor Reform.
Lab test regulatory and reimbursement reform.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN MEDICAL ASSOCIATION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Physician Payment Reform.
Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
MCKESSON CORPORATION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ILLUMINA, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
General discussions related to FDA regulation of diagnostics.
General discussions related to Medicare reimbursement for diagnostic tests.
General trade issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Prescription drug payment reform. Supply Chain. 340B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EMD SERONO INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Drug pricing policy. Implementation of Inflation Reduction Act of 2022. S.864 - HELP Copays Act.
PBM Reform. 340B Program. Supply chain. Issues pertaining to reproductive health and access and coverage of infertility treatments and care.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.
Prescription Drug Pricing Policy. Supply Chain Issues.
Prescription drug pricing policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FOX CORPORATION via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Online privacy. Media ownership issues. Streaming issues.
Advertising issues.
Policy issues impacting television and media business. Retransmission consent. Spectrum-related issues.
ALKERMES, INC. via TODD STRATEGY GROUP
2025 · fourth_quarter · Q4
Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MILLIPORESIGMA via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2025 · third_quarter · Q3
Prescription drug pricing. Medical countermeasure development and procurement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS)
NOVARTIS, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation. Most Favored Nation (MFN) policy.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832/H.R.1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025.
MERCK & CO., INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues.
Drug Pricing. S.864 - HELP Copays Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPORATION via TODD STRATEGY GROUP
2025 · third_quarter · Q3
General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ILLUMINA, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
General discussions related to the Food and Drug Administration's regulation of diagnostics. General health care procurement policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MILLIPORESIGMA via TODD STRATEGY GROUP
2025 · third_quarter · RR
Domestic manufacturing.
2025 · third_quarter · RR
Prescription drug pricing. Medical countermeasure development and procurement.
WINE & SPIRITS WHOLESALERS OF AMERICA via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Tax policy related to qualified business investment tax credit.
Filing targets: SENATE
VAXART INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Vaccine policy.
Filing targets: Health & Human Services, Dept of (HHS)
VALISURE via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Drug product quality assurance.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2025 · third_quarter · Q3
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE ORTHOFORUM via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Physician Reimbursement. Physician-owned hospitals. Medicare and Medicaid Issues. Payment Reform. Price transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Prior Authorization for Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
MEDICAL COUNTERMEASURES COALITION via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Sustainability of the public health emergency medical countermeasure enterprise.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KALDEROS, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Government pricing discounts. Claims adjudication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Prescription drug payment reform. Supply Chain. 340B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.
Prescription drug payment reform. Supply chain. Strategic National Stockpile.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FERRING PHARMACEUTICALS INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Issues pertaining to reproductive health and access and coverage of infertility treatments and care. Issues related to infectious disease and hospital acquired infections.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PERIMETER SYSTEMS, INC. FKA GINKGO BIOSECURITY via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Biosecurity Issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIODESIX, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare reimbursement for diagnostics. Medicare Contractor Reform.
Lab test regulatory and reimbursement reform.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.
Prescription Drug Pricing Policy. Supply Chain Issues.
Prescription drug pricing policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN MEDICAL ASSOCIATION via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Physician Payment Reform.
Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via TODD STRATEGY GROUP
2025 · third_quarter · Q3
Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WINE & SPIRITS WHOLESALERS OF AMERICA via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Tax policy related to qualified business investment tax credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VALISURE via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Drug product quality assurance.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VAXART INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Vaccine policy.
Filing targets: Health & Human Services, Dept of (HHS)
WINE & SPIRITS WHOLESALERS OF AMERICA via TODD STRATEGY GROUP
2025 · second_quarter · RR
Tax policy related to qualified business investment tax credit.
VALISURE via TODD STRATEGY GROUP
2025 · second_quarter · RR
Drug product quality assurance.
VAXART INC. via TODD STRATEGY GROUP
2025 · second_quarter · RR
Vaccine policy.
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Copyright issues. Intellectual property protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2025 · second_quarter · Q2
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE ORTHOFORUM via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Physician Reimbursement. Physician-owned hospitals. Medicare and Medicaid Issues. Payment Reform. Price transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Traffic policies.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYRIAD GENETICS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Prior Authorization for Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
MERCK & CO., INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues.
Drug Pricing. S.864 - HELP Copays Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL COUNTERMEASURES COALITION via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Sustainability of the public health emergency medical countermeasure enterprise.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MED CLAIMS COMPLIANCE CORPORATION via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare and VA Claims Processing through AI.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPORATION via TODD STRATEGY GROUP
2025 · second_quarter · Q2
General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
KALDEROS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Government pricing discounts. Claims adjudication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLUMINA, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
General discussions related to the Food and Drug Administration's regulation of diagnostics. General health care procurement policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Prescription drug payment reform. Supply Chain. 340B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.
Prescription drug payment reform. Supply chain. Strategic National Stockpile.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FLEXCARE via TODD STRATEGY GROUP
2025 · first_quarter · 1T
Healthcare Policy Regarding Hospital Workforce.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Issues pertaining to reproductive health and access and coverage of infertility treatments and care. Issues related to infectious disease and hospital acquired infections.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PERIMETER SYSTEMS, INC. FKA GINKGO BIOSECURITY via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Biosecurity Issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIODESIX, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare reimbursement for diagnostics. Medicare Contractor Reform.
Lab test regulatory and reimbursement reform.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMGEN INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.
Prescription Drug Pricing Policy. Supply Chain Issues.
Prescription drug pricing policy.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN MEDICAL ASSOCIATION via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Physician Payment Reform.
Medicare and Medicaid Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALKERMES, INC. via TODD STRATEGY GROUP
2025 · second_quarter · Q2
Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
U.S. CHAMBER OF COMMERCE GLOBAL INNOVATION POLICY CENTER via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Copyright issues Intellectual property protection. March-in rights.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TRUIST FINANCIAL CORPORATION via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Banking Regulatory Reform Issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TODD STRATEGY GROUP
2025 · first_quarter · Q1
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE ORTHOFORUM via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Physician Reimbursement. Physician-owned hospitals. Medicare and Medicaid Issues. Payment Reform. Price transparency.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYRIAD GENETICS, INC. via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Prior Authorization for Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES
MERCK & CO., INC. via TODD STRATEGY GROUP
2025 · first_quarter · Q1
340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues.
Drug Pricing. S.864 - HELP Copays Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDICAL COUNTERMEASURES COALITION via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Sustainability of the public health emergency medical countermeasure enterprise.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MED CLAIMS COMPLIANCE CORPORATION via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Medicare and VA Claims Processing through AI.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPORATION via TODD STRATEGY GROUP
2025 · first_quarter · Q1
General Medicare/Medicaid Issues. Prescription Drug Price Reform. Transparency Requirements. Emergency Preparedness.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
KALDEROS, INC. via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Government pricing discounts. Claims adjudication.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ILLUMINA, INC. via TODD STRATEGY GROUP
2025 · first_quarter · Q1
General Discussions related to the Food and Drug Administration's regulation of diagnostics. General health care procurement policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Prescription drug payment reform. Supply Chain. 340B.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENENTECH, INC. via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.
Prescription drug payment reform. Supply chain. Strategic National Stockpile.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
FLEXCARE via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Healthcare Policy Regarding Hospital Workforce.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS INC. via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Issues pertaining to reproductive health and access and coverage of infertility treatments and care. Issues related to infectious disease and hospital acquired infections.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PERIMETER SYSTEMS, INC. FKA GINKGO BIOSECURITY via TODD STRATEGY GROUP
2025 · first_quarter · Q1
Biopharma manufacturing. Bio-Detection Issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Antitrust enforcement and reform. Copyright and content carriage issues.
Corporate tax issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Tariffs.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE